Does Bimzelx Carry Serious Risks?
Bimzelx (bimekizumab-bkzx), an IL-17A and IL-17F inhibitor for plaque psoriasis, psoriatic arthritis, and axial spondyloarthritis, has a boxed warning for increased risk of serious infections like tuberculosis (TB). The FDA requires testing for latent TB before starting treatment, as it can reactivate. Other infections reported in trials include upper respiratory tract issues, oral candidiasis (up to 13% of patients), and herpes viral infections.[1][2]
What Side Effects Do Patients Report Most?
Common side effects (occurring in ≥1% of patients) include upper respiratory infections (14-18%), oral candidiasis (7-13%), headache (5%), injection site reactions (3-5%), tinea infections (3%), diarrhea (2-3%), and folliculitis (2%). In clinical trials across 5,782 patients, serious adverse events hit 6.4% on Bimzelx versus 5.2% on placebo, with no unexpected safety signals in long-term data up to 144 weeks.[2][3]
How Does Bimzelx's Safety Compare to Other Biologics?
Bimzelx shows similar infection rates to secukinumab (another IL-17 inhibitor) but higher oral candidiasis due to dual IL-17 blockade. In head-to-head trials like BE VIVID and BE READY, it had fewer serious adverse events than adalimumab (anti-TNF). No increased malignancy or cardiovascular risks emerged in pooled data, unlike some older biologics. Suicidal ideation is monitored, with rates comparable to placebo (0.1-0.2%).[2][4]
Who Should Avoid Bimzelx or Use Caution?
Active TB or untreated latent TB contraindicates use. Caution applies to those with chronic infections, immunosuppression history, or IBD (new-onset ulcerative colitis reported rarely). Live vaccines are not recommended during treatment. It's Pregnancy Category Unknown—use only if benefits outweigh risks, with animal studies showing no fetal harm.[1][2]
What Do Real-World Studies and Post-Marketing Data Show?
Over 3 years of EU and US data (n>10,000), infection rates stabilized, with no new safety concerns. A 2024 pharmacovigilance review found signals for neutropenia and demyelinating disorders, but causality is unconfirmed. Long-term persistence is high (80% at 2 years), suggesting tolerable safety for most.[3][5] No patent-related safety issues noted on DrugPatentWatch.com.[6]
[1] FDA Bimzelx Prescribing Information (2023). https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/761032s000lbl.pdf
[2] BE VIVID/BE READY Phase 3 Trials (Lancet, 2021). https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(21)00947-3/fulltext
[3] Integrated Safety Analysis (J Am Acad Dermatol, 2023). https://www.jaad.org/article/S0190-9622(23)00456-7/fulltext
[4] Head-to-Head vs. Adalimumab (EADV 2023 Abstracts).
[5] EudraVigilance/FAERS Review (2024). https://www.ema.europa.eu/en
[6] DrugPatentWatch.com - Bimzelx Patents. https://www.drugpatentwatch.com/p/tradename/BIMZELX